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The polymorphic fungus Candida albicans is one of the most versatile opportunistic pathogens in humans.
Many organs of the human body are potential targets for infection by this pathogen, but infection is commonly
localized in the gastrointestinal tract, an environment providing anaerobic growth conditions. We describe a
chemically defined anaerobic growth medium for four strains of Candida albicans (A72, SC5314, MEN, and
10261). It is a defined liquid glucose-phosphate-proline growth medium supplemented with oleic acid, nicotinic
acid, and ammonium chloride. The cells did not require or respond to added ergosterol. Oleic acid and nico-
tinic acid are growth factors which are required only for the anaerobic growth of C. albicans. An important tech-
nical feature of this study was the use of anaerobically grown inocula to study anaerobic growth. Anaerobically,
the cells grew exclusively as mycelia at 25, 30, and 37°C. The doubling time at 30°C was ca. 20 h. The cells did not
produce farnesol and did not respond to exogenous farnesol, and they were resistant to the highest tested levels
of amphotericin B and four of the azole antifungals. We suggest that the anaerobic growth of C. albicans may
contribute to the trailing end point phenomenon and the resistance of C. albicans biofilms to antifungal drugs.
The dimorphic fungus Candida albicans is one of the most
commonly isolated fungal pathogens in humans. Infections
with C. albicans, called candidoses, occur predominantly in
immunosuppressed patients (AIDS, cancer treatment, and
transplant patients). For AIDS patients, candidosis has been
shown to be the most common human immunodeficiency virus-
associated opportunistic infection (19). C. albicans is also as-
sociated with 78% of fungal nosocomial infections and over
10% of all nosocomial infections documented (19). The annual
cost of treating candidal infections in the United States has
been estimated at 1 billion dollars (22).
The aerobic growth of C. albicans has been studied exten-
sively, but even though C. albicans has often been referred to
as a facultative anaerobe (25), papers describing anaerobic
growth are rare. Our literature search recovered only eight
articles (10, 16, 17, 33, 35–38), two of which (16, 33) describe
survival under anaerobic conditions rather than actual anaer-
obic growth and three more of which (10, 17, 38) merely
confirm that anaerobic growth is possible. However, Szawat-
kowski and Hamilton-Miller (35) reported that 20 strains of
C. albicans could grow anaerobically on either Sabouraud agar
or brucella agar supplemented with 10% whole horse blood,
and Webster and Odds (37) showed that seven Candida spe-
cies, including C. albicans, could grow anaerobically on four
media: Eagle’s minimal medium with 10% horse serum, a
peptone-glucose broth, and two defined but complicated me-
dia (yeast nitrogen base-glucose broth and yeast nitrogen base-
asparagine-glucose-phosphate [YAGP] broth). However, in all
cases the experiments were conducted with aerobically grown
inocula and GasPak anaerobic systems. Thus, the experiments
studied both steady-state anaerobic conditions and an aerobic-
to-anaerobic adaptation of indeterminate length. To gauge the
likely duration of an aerobic-to-anaerobic adaptive period, we
note that when grown anaerobically, the yeast Saccharomyces
cerevisiae requires ergosterol as an added growth factor (1).
However, when an aerobically grown culture of S. cerevisiae is
inoculated into anaerobic medium that does not contain er-
gosterol, growth stops only after five to seven generations (27).
This comparative lack of interest in anaerobic growth is
surprising for two reasons. First, in many cases C. albicans in-
fections spread into the body from the anaerobic gastrointes-
tinal tract (19, 25), and second, the interiors of many biofilms
are anaerobic (9). Furthermore, the accurate assessment of an
organism’s nutritional requirements requires the use of chem-
ically defined media, and reproducible anaerobically grown
inocula require liquid media. We now describe a minimal de-
fined liquid medium for the anaerobic growth of C. albicans,
consisting of a glucose-phosphate-proline (GPP) medium (13,
18) supplemented with oleic acid, nicotinic acid, and ammo-
nium chloride.
Effective antifungal antibiotics are rare due to few fungus-
specific targets and the rapid development of drug resistance.
Research has been done to test the sensitivity and resistance of
C. albicans cells grown aerobically (21, 32) and anaerobically
(35, 36, 38) to several antifungal agents. We have tested five
classes of antifungal agents on cells grown anaerobically: poly-
enes, allylamines, azoles, zaragozic acid B, and cerulenin. Poly-
enes, such as amphotericin B, bind to ergosterol present in the
cell membrane, causing damage to the cell membrane and
leakage of intracellular ions (31). Azoles such as fluconazole,
ketoconazole, voriconazole, and itraconazole block ergosterol
biosynthesis by inhibiting the cytochrome P450 responsible for
14 demethylation of lanosterol (31). Additionally, the allyl-
amine terbinafine inhibits squalene epoxidase (31), zaragozic
acid B inhibits squalene synthase (14), and cerulenin inhibits
fatty acid synthesis (26). We found that anaerobically grown
cells were at least fourfold more resistant than aerobically
* Corresponding author. Mailing address: School of Biological Sci-
ences, University of Nebraska, Lincoln, NE 68588-0666. Phone: (402)
472-2253. Fax: (402) 472-8722. E-mail: knickerson1@unl.edu.
† Present address: Division of Natural Sciences, Lewis-Clark State
College, Lewiston, ID 83501.
2350
 at U
N
IV
 O
F
 N
E
B
R
A
S
K
A
-LIN
C
O
LN
 on S
eptem
ber 5, 2007 
aac.asm
.org
D
ow
nloaded from
 
grown cells to all eight of the antifungals tested. In particular,
they were resistant to the highest levels tested for amphotericin
B and the four azole antifungals. Our results suggest that the
anaerobic growth of C. albicans may contribute to the trailing
end point phenomenon (21) and the marked resistance of C.
albicans biofilms to antifungal drugs (3, 20, 23). The twin pur-
poses of this study were to define the basic biology of anaerobic
growth in C. albicans and to show how anaerobic conditions
greatly enhance resistance to common antifungals. It was not
to describe a better method of antifungal susceptibility testing.
MATERIALS AND METHODS
Strains. C. albicans A72 and 10261 were obtained from Patrick Sullivan,
University of Otago, Dunedin, New Zealand; strain MEN was obtained from
Richard Cannon, University of Otago; and strain SC5314 was obtained from
Burk Braun, University of California at San Francisco.
Media. GPP is the growth medium for fungi described by Kulkarni and Nick-
erson (18). Normal GPP medium contains the following (per 900 ml of distilled
water): 4.0 g of KH2PO4, 3.2 g of NaH2PO4, 1.2 g of L-proline, and 0.7 g of
MgSO4  7H2O. After the medium was autoclaved, 100 ml of 20% (wt/vol)
glucose, 1 ml of a vitamin mix, and 0.25 ml of a mineral mix were added. The
vitamin mix contains the following (per 100 ml of 20% ethanol): 2 mg of biotin,
20 mg of thiamine-HCl, and 20 mg of pyridoxine-HCl. The mineral mix contains
the following (per 100 ml of 0.1 N HCl): 0.5 g of CuSO4  5H2O, 0.5 g of
ZnSO4  7H2O, 0.8 g of MnCl2  4H2O, and 0.5 g of FeSO4. The vitamin mix and
mineral mix were filter sterilized through 0.2-m-pore-size Whatman (Maid-
stone, United Kingdom) cellulose nitrate filters and stored at 4°C. For anaerobic
growth of C. albicans, regular GPP medium (10 ml) was supplemented with 200
l of 1 mM oleic acid in 100% methanol, 200 l of 4 mM nicotinic acid, and 1
ml of 500 mM NH4Cl. The pH of this complete defined growth medium was 5.
Aerobic inoculum preparation. The modified glucose-salt-biotin growth me-
dium (13) used for preparing aerobic C. albicans cell stocks contains the follow-
ing (per liter of distilled water): 1 g of (NH4)2SO4, 2 g of KH2PO4, 50 mg of
MgSO4  7H2O, 50 mg of CaCl2  2H2O, 1 g of peptone, and 5 g of yeast nitrogen
base. After this medium was autoclaved, 10.25 ml of 50% (wt/vol) glucose and 0.4
ml of the GPP vitamin stock were added aseptically. This vitamin mix contains
biotin, pyridoxine, and thiamine (18). Cells were harvested after 26 to 28 h of
growth, washed three times in 50 mM potassium phosphate buffer (pH 6.5), and
stored at 4°C in the same buffer at a cell density of ca. 2  109 cells/ml.
Anaerobic-medium preparation. The Hungate technique for growing stringent
anaerobes (7) was employed. The anaerobic medium was prepared in 25-ml
anaerobic tubes (Bellco). To the complete defined medium were added increas-
ing concentrations of resazurin (0.001 to 0.005%) to verify anaerobiosis of the
medium and 10 mg of solid cysteine to decrease the redox potential of the
medium. The medium was bubbled with ultrahigh-purity nitrogen for 15 min at
room temperature and then autoclaved for 30 min at 121°C. The color of the
medium changed from purple to pale yellow, confirming that the tubes were
anaerobic.
Anaerobic inoculum preparation. An aerobic inoculum of 2  106 cells/ml was
used to inoculate 10 ml of complete defined anaerobic medium. The culture was
incubated at 30°C, and growth was monitored by measuring the optical density
(OD) at 660 nm (Spectronic 20; Milton Roy) every 4 h and by examining cellular
morphology by phase-contrast microscopy. When the cells were in the logarith-
mic phase at an OD of 0.8, a 500-l portion was used to inoculate another 10 ml
of anaerobic medium. This second tube was designated the anaerobic culture of
C. albicans. During growth, the pH decreased from a pH of 5 to a pH of 4.
Antifungal susceptibility. The following antifungal drugs were used in this
study: amphotericin B, fluconazole, ketoconazole, clotrimazole, miconazole,
zaragozic acid B, terbinafine, and cerulenin. All were prepared as stock solutions
at 1 mg of drug/ml of sterile water and stored frozen, except for cerulenin, with
which the stock solution was in ethanol. C. albicans A72 cells were inoculated at
106 cells/ml into our complete defined anaerobic growth medium at 30°C, and
growth was monitored by OD for either 48 h (aerobic) or 5 days (anaerobic). The
aerobic and anaerobic susceptibility measurements differed only in that the
aerobic cultures were transferred to 25-ml Erlenmeyer flasks and shaken at 200
rpm. Fluconazole and zaragozic acid B were gifts from Pfizer and Merck, re-
spectively. The terbinafine was purchased from ChemPacific, Inc., Baltimore,
Md., and the other antifungals were purchased from Sigma, St. Louis, Mo.
RESULTS
Anaerobic growth. C. albicans A72 did not grow anaerobi-
cally in unsupplemented GPP liquid medium. However, it did
grow when the medium was supplemented with either 1%
yeast extract (data not shown) or a combination of oleic acid,
nicotinic acid, and ammonium chloride (Fig. 1). All of our
subsequent work focused on the complete defined medium
containing oleic acid, nicotinic acid, and ammonium chloride.
Each of the supplements was necessary; removal of either
ammonium, proline, nicotinic acid, or oleic acid individually
gave much-reduced growth (Fig. 1). However, these were the
only supplements identified as necessary. Added L-arginine,
betaine, bile salts, ergosterol, fumarate, or potassium nitrate
did not improve growth at either 30 or 37°C. With an anaer-
obically grown inoculum of ca. 106 cells per ml, it took ca. 110 h
to reach the stationary phase at 30°C (Fig. 1). Calculated
graphically, this indicates an anaerobic doubling time of 20 h.
This value is in contrast to the aerobic doubling time for C.
albicans A72 of ca. 2 h when grown with shaking in either GPP
medium or our complete defined medium. The cultures were
completely anaerobic throughout growth, as measured by the
resazurin indicator dyes. We have conducted six successive
transfers with this complete defined medium, and the growth
parameters of the sixth were identical to those of the first.
Equivalent anaerobic growth has been obtained on complete
defined medium with C. albicans strains A72, MEN, SC5314,
and 10261. All of our subsequent work used C. albicans A72.
Morphology of anaerobically grown cells. The dominant
morphology for anaerobically grown cells was mycelia. With an
aerobically grown inoculum, anaerobic cultures at 25, 30, and
37°C grew initially as budding yeasts and then gradually shifted
to the hyphal morphology and stayed as mycelia. When exam-
ined by phase-contrast microscopy, the 30°C culture had
reached ca. 50% mycelia by 48 h and 90% mycelia by 72 h, and
by the stationary phase (4 to 5 days), dense mycelial mats were
prevalent (Fig. 2). No spiral hyphae were observed (16). The
conversion to mycelia occurred more slowly at 25°C. With an
FIG. 1. Anaerobic growth of C. albicans cells at 30°C. E, growth in
the complete minimal medium; F, growth in medium without proline;
f, growth in medium without NH4Cl; ‚, growth in medium without
oleic acid; e, growth in medium without nicotinic acid.
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anaerobically grown inoculum, the cells remained ca. 95%
mycelial throughout growth at 25, 30, and 37°C.
It is well known that under aerobic conditions germ tubes or
hyphae are triggered at 37°C by either L-proline, serum, or
N-acetyl-D-glucosamine (13, 25). Consequently, we wondered
whether the L-proline in our complete defined anaerobic me-
dium was necessary for the production of mycelia. It was not.
Equivalent percentages of mycelia were observed when L-pro-
line was replaced with either L-arginine or L-phenylalanine,
although in both cases the growth rates were somewhat lower
(data not shown).
Farnesol. We next investigated whether anaerobically grown
C. albicans cells either produced farnesol or responded to
exogenous farnesol. They did neither. When examined by our
standard gas chromatography-mass spectrometry detection
system (13), no extracellular farnesol was detected in superna-
tants from cells which had been grown anaerobically at 30°C
for 4 to 5 days. That is, there was less than 0.001 g of farnesol
per mg (dry weight) of cells. In contrast, aerobically grown cells
produce ca. 0.18 to 0.22 g of farnesol/mg (15). Furthermore,
during anaerobic growth, C. albicans did not respond to far-
nesol. In complete defined medium with farnesol present from
time zero, the cell growth rates and morphologies remained
unchanged, with farnesol concentrations ranging from 0 to 1.2
mM. The same results occurred at both 30 and 37°C and with
both aerobically and anaerobically grown inocula. In particu-
lar, the kinetics for the yeast-to-mycelium conversion of an
aerobically grown inoculum were the same with and without
farnesol. This concentration of farnesol (1.2 mM) represents
the maximum solubility of farnesol in water. In contrast, aer-
obic C. albicans exhibits a 50% conversion of mycelia to yeast
cells at only 1.2 M farnesol (34).
Antifungals. Our studies revealed that anaerobically grown
cells were much more resistant than aerobically grown cells
to eight antifungals. Anaerobically grown C. albicans was re-
sistant to all concentrations of amphotericin B, clotrimazole,
fluconazole, miconazole, and ketoconazole (Table 1). Also,
anaerobically grown cells were 4, 8, and 16 times more resistant
than aerobically grown cells to cerulenin, terbinafine, and zara-
gozic acid B, respectively (Table 1). The experimental design
whose results are shown in Table 1 used an aerobic inoculum
for aerobic growth and an anaerobic inoculum for anaerobic
growth. We also employed a crossover design in which both
aerobic and anaerobic inocula were used for both aerobic and
anaerobic growth. The crossover design was used to test for
miconazole sensitivity. Since the same medium was used for all
these experiments, the presence or absence of oxygen was the
only variable. With both inocula, the MIC of miconazole was 4
g/ml during aerobic growth and 80 g/ml during anaerobic
growth.
The morphology of the cells growing anaerobically in the
presence of 4 to 16 g of amphotericin B, fluconazole, keto-
conazole, zaragozic acid B, and cerulenin per ml was the same
as that of cells growing in the absence of these agents. Mycelia
were present continuously. This observation is in contrast to
what was observed for aerobic C. albicans, with which subin-
hibitory concentrations of the azole antifungals inhibit mycelial
development and maintain the cells in the yeast morphology
(12, 25). This morphological conversion is likely due to the
secretion of excess farnesol by azole-treated C. albicans (15).
However, for sublethal levels of terbinafine, the anaerobic cells
grew as yeast cells; the mycelial form was inhibited.
Physiological versus genetic. Stationary-phase anaerobically
grown cells were diluted and counted as CFU on yeast extract-
FIG. 2. Morphology of C. albicans cells grown under anaerobic conditions after 72 h. Bars  200 m (A) and 50 m (B).
TABLE 1. Inhibitory concentrations of cell inhibitors and
antifungal compounds for aerobically and anaerobically
grown C. albicans A72
Compound
Inhibitory concn (g/ml)a
Aerobic growth Anaerobic growth
Amphotericin B 0.5 20 (not reached)
Cerulenin 1 4
Terbinafine 4 32
Zaragozic acid B 0.5 8
Clotrimazole 2 16 (not reached)
Fluconazole 8 40 (not reached)
Miconazole 4 16 (not reached)
Ketoconazole 4 4 (not reached)
a Concentration at which no growth was evident after 48 h (aerobic) or 5 days
(anaerobic). C. albicans A72 grown anaerobically appeared to be resistant to
amphotericin B and the four azole antifungals, in that the cells still grew at the
highest concentrations tested.
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peptone-dextrose agar. Ten colonies were picked at random
and grown aerobically in unsupplemented GPP medium. All 10
strains were equally as sensitive to fluconazole as the starting
C. albicans strain, which had never been grown anaerobically.
Therefore, the antibiotic resistance shown in Table 1 is not due
to selection for antibiotic-resistant mutants.
DISCUSSION
We have devised a defined liquid medium for the anaerobic
growth of C. albicans. It consists of the GPP medium that we
use for the aerobic growth of C. albicans (13) supplemented
with oleic acid, nicotinic acid, and ammonium chloride. Ergos-
terol is not required. All anaerobic protocols used the Hungate
technique for stringently growing anaerobes (7). Anaerobic
growth was much slower than aerobic growth, and the cell
morphology during anaerobic growth was filamentous at all
temperatures tested, i.e., 25, 30, and 37°C. The mycelial growth
is a consequence, direct or indirect, of anaerobiosis rather than
the stringent conditions of the Hungate procedure for achiev-
ing anaerobiosis (7). The Hungate procedure (7) includes L-
cysteine (1 mg/ml, 8.3 mM). However, it is unlikely that this
cysteine contributes to mycelial growth, because Nickerson and
van Rij (24) showed that 1 to 10 mM L-cysteine shifted the
morphology of aerobic C. albicans towards that of yeast cells,
not towards that of mycelia. Our observation of anaerobic
mycelia agrees with the previous findings of Webster and Odds
(37). Additionally, Szawatkowski and Hamilton-Miller (35) re-
ported that stellate (more filamentous) colonies were formed
anaerobically, unlike the creamy colonies formed aerobically
(35).
Remembering that C. albicans forms farnesol from farnesyl
pyrophosphate (14), three observations regarding the anaero-
bic growth of C. albicans are consistent with one another. First,
anaerobically grown cells do not excrete farnesol. Second, dur-
ing growth the morphological progression is from yeast cells to
mycelia rather than vice versa as it is in air, where farnesol
would be produced (13). Third, anaerobic cells appear to be
insensitive to the azole and polyene antibiotics. These three
observations could all result from reduced, altered, or absent
carbon flow through the sterol pathway under anaerobic
growth conditions. We conclude that anaerobically grown C.
albicans does not use the same quorum-sensing system that the
organism uses when it is grown aerobically (13). Two previous
reports also examined the effectiveness of antifungals during
the anaerobic growth of C. albicans. Using yeast morphology
agar and the paper disk method in GasPak jars, Uno et al. (36)
showed that ketoconazole inhibited growth aerobically but not
anaerobically. In contrast, Szawatkowski and Hamilton-Miller
(35) incorporated various levels of amphotericin B and clo-
trimazole into Sabouraud agar. They reported that the MICs
were little changed for aerobically versus anaerobically grown
cells. However, in comparing anaerobic drug sensitivity data, a
key technical feature is the use of an anaerobically grown
inoculum. With an anaerobic inoculum, the cells have already
lost their characteristic aerobic sterol composition. Otherwise,
drug sensitivity would be measured while the aerobic sterol
composition was in the process of being diluted out. As an
example of the time frame needed for sterol dilution, when an
aerobically grown culture of S. cerevisiae is inoculated into an
anaerobic medium in the absence of sterols, growth stops only
after five to seven generations (27).
Added nutritional requirements for the anaerobic growth of
fungi are well known. Anaerobically, S. cerevisiae requires both
ergosterol (1) and an unsaturated fatty acid, usually oleic acid
(2), while Mucor rouxii requires nicotinic acid (6). We have
added to this list by finding that C. albicans requires both oleic
acid and nicotinic acid. Recognition of these added nutritional
requirements for C. albicans provides further confirmation that
the conditions employed were indeed anaerobic.
An understanding of nutritional requirements should also
prove useful in interpreting physiological aspects of anaerobic
growth. For instance, Webster and Odds (37) noted marked
differences in the cell yields for anaerobically grown C. albi-
cans. For the four media they studied (Eagle’s minimal me-
dium with 10% horse serum, YAGP broth, yeast nitrogen base-
glucose broth, and peptone-glucose broth), the cell yields were
in the ratio of ca. 1:2:3:4, respectively. These differences could
be due to altered glucose content, as suggested by the authors
(37), or they could be due to differences in available oleic or
nicotinic acid.
Significantly, C. albicans did not require ergosterol for
growth. This finding has ample precedent. (i) S. cerevisiae re-
quires ergosterol for anaerobic growth (1), but Schizosaccha-
romyces japonicus does not (8). (ii) In two cases (35, 38), the
anaerobic growth of C. albicans was achieved without added
ergosterol, although in both cases the media contained pep-
tone and yeast extract. (iii) The erg11 gene is an essential gene
in S. cerevisiae but not in C. albicans (5, 32). Erg11p is the
target for the azole antifungals (31). (iv) D10 is a slowly grow-
ing cytochrome P450-deficient mutant of C. albicans which
does not produce ergosterol but also does not require ergos-
terol (4). Thus, there are similarities between the anaerobic
growth of C. albicans A72 and the aerobic growth of C. albi-
cans D10 (4). (v) If we assume that C. albicans is well adapted
for anaerobic growth in the gastrointestinal tract, where ergos-
terol is not available, then it is also reasonable to assume that
it is able to cope with the absence of ergosterol. In this light,
the suggestion has been made (11) that a two-step reaction of
dehydrogenation and hydration could accomplish single-oxy-
gen hydroxylation, as in ergosterol biosynthesis, with the in-
serted oxygen coming from water, not O2. The exact physio-
logical and molecular mechanisms which allow anaerobically
grown C. albicans to be resistant to the azole antifungals is
being investigated in our laboratory.
The results presented here demonstrate that C. albicans is
able to grow anaerobically in vitro and that other targets must
be taken into consideration when this pathogen grows under
anaerobiosis. Clinical implications of this study are apparent. If
patients with intestinal candidosis fail to respond to azoles and
polyenes, which are the most used antifungals today, other
antifungals must be taken into consideration.
Exact parallels cannot be drawn between our in vitro results
and clinical practice. However, the recognition that anaerobi-
cally grown C. albicans cells are more resistant to some anti-
fungals than aerobically grown ones provides an alternate
explanation for two aspects of antifungal testing. First, the
trailing end point phenotype in antifungal susceptibility testing
(21) describes incomplete growth inhibition, even at very high
concentrations of the antifungal. Thus, an in vitro-in vivo dis-
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crepancy is created; for instance, mice infected with a certain
strain of C. albicans responded to fluconazole therapy despite
the fact that in vitro testing indicated that the strain was not
susceptible to fluconazole (30). One cause of the trailing
growth phenotype may be anaerobic growth in the automated
microtiter plates in which the in vitro susceptibility measure-
ments were made. The geometry of the individual wells would
make it difficult to achieve adequate aeration. Repeating the in
vitro-in vivo comparison with fully aerated cultures should
resolve this dilemma. Second, C. albicans cells exhibit greater
resistance to fluconazole and other antifungal drugs when they
are in biofilms than when they are not (3, 20, 23). However, the
interiors of many microbial biofilms are highly anaerobic (9),
and at least three features of C. albicans biofilms could be
explained if their interiors were anaerobic or partially anaer-
obic. (i) Mature biofilms contain more than 95% true hyphae
(29). (ii) Although it is known that drug efflux determinants are
expressed within biofilms (23, 28), the mechanism that gives
rise to the expression of these genes is unknown (20). It could
be due to anaerobiosis. (iii) Biofilms appear to have an intrin-
sic drug resistance. Ramage et al. (28) demonstrated that C.
albicans cells within a biofilm express genes encoding drug
resistance determinants but that biofilms formed from mutants
lacking these genes still exhibit antifungal resistance. Our lab-
oratory is currently investigating the potential mechanisms for
the exceptional drug resistance shown by anaerobically grown
C. albicans.
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